Literature DB >> 11156351

The early fall in levels of S-100 beta in traumatic brain injury.

R G Jackson1, G S Samra, J Radcliffe, G H Clark, C P Price.   

Abstract

Protein S-100 beta has been suggested as a prognostic marker in traumatic brain injury. However, little is known of its behaviour in the immediate post-injury period. With Ethics Committee approval, we recruited 30 patients with a history of head injury presenting to our Accident and Emergency Department. Blood was taken on arrival and at four hours post-injury. Serum S-100 beta was estimated using an immunoluminometric assay. Levels of S-100 beta were seen to fall rapidly with time. Half-time was distributed non-parametrically with a median of 198 minutes. Using the Mann-Whitney U test we found a statistically significant difference between non-desirable (Glasgow Outcome Score 1-3) and desirable (Glasgow Outcome Score 4-5) outcome on admission (p = 0.0155) but not at four hours (p = 0.1336). Levels of S-100 beta fell rapidly after its release following traumatic brain injury. Time after injury is therefore critical in assessing the significance of levels of S-100 beta, and sampling should be as early as possible to gain maximum information. If S-100 beta is to be assessed as a monitor of ongoing brain injury in the intensive therapy unit sampling must be frequent (e.g. every 4 hours) to be able to detect rises in serum levels before they have decayed to baseline.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156351     DOI: 10.1515/CCLM.2000.179

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  18 in total

Review 1.  Point of care testing.

Authors:  C P Price
Journal:  BMJ       Date:  2001-05-26

2.  Initial predictive factors of outcome in severe non-accidental head trauma in children.

Authors:  Didier Scavarda; Charline Gabaudan; Fabrice Ughetto; Frederic Lamy; Vanessa Imada; Gabriel Lena; Olivier Paut
Journal:  Childs Nerv Syst       Date:  2010-05-12       Impact factor: 1.475

3.  Serial measurement of S100B and NSE in pediatric traumatic brain injury.

Authors:  Dae-Won Park; Seong-Hyun Park; Sung-Kyoo Hwang
Journal:  Childs Nerv Syst       Date:  2018-08-31       Impact factor: 1.475

Review 4.  Clinical applications of biomarkers in pediatric traumatic brain injury.

Authors:  Simon J I Sandler; Anthony A Figaji; P David Adelson
Journal:  Childs Nerv Syst       Date:  2009-11-10       Impact factor: 1.475

5.  Assessing bicycle-related trauma using the biomarker S100B reveals a correlation with total injury severity.

Authors:  E P Thelin; E Zibung; L Riddez; C Nordenvall
Journal:  Eur J Trauma Emerg Surg       Date:  2015-10-21       Impact factor: 3.693

6.  S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury.

Authors:  Shruti V Kabadi; Bogdan A Stoica; Danna B Zimmer; Lauriaselle Afanador; Kara B Duffy; David J Loane; Alan I Faden
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

7.  The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.

Authors:  Andrea Kleindienst; Christian Schmidt; Hans Parsch; Irene Emtmann; Yu Xu; Michael Buchfelder
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-07-08

8.  Head injury outcome prediction in the emergency department: a role for protein S-100B?

Authors:  W J Townend; M J Guy; M A Pani; B Martin; D W Yates
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

9.  S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury.

Authors:  Akash Goyal; Michelle D Failla; Christian Niyonkuru; Krutika Amin; Anthony Fabio; Rachel P Berger; Amy K Wagner
Journal:  J Neurotrauma       Date:  2013-06-01       Impact factor: 5.269

10.  Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery.

Authors:  J D Guingab-Cagmat; E B Cagmat; R L Hayes; J Anagli
Journal:  Front Neurol       Date:  2013-05-31       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.